Next Article in Journal
Novel Boronate Probe Based on 3-Benzothiazol-2-yl-7-hydroxy-chromen-2-one for the Detection of Peroxynitrite and Hypochlorite
Next Article in Special Issue
Integrated Network Pharmacology Analysis and In Vitro Validation Revealed the Potential Active Components and Underlying Mechanistic Pathways of Herba Patriniae in Colorectal Cancer
Previous Article in Journal
Exploring Gunnera tinctoria: From Nutritional and Anti-Tumoral Properties to Phytosome Development Following Structural Arrangement Based on Molecular Docking
Previous Article in Special Issue
Fishing of α-Glucosidase’s Ligands from Aloe vera by α-Glucosidase Functionalized Magnetic Nanoparticles
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Quassinoids from the Roots of Eurycoma longifolia and Their Anti-Proliferation Activities

1
School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, China
2
Center for Bioactive Natural Molecules and Innovative Drugs Research, College of Pharmacy, Jinan University, Guangzhou 510632, China
3
Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou 510632, China
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Molecules 2021, 26(19), 5939; https://doi.org/10.3390/molecules26195939
Submission received: 30 August 2021 / Revised: 24 September 2021 / Accepted: 27 September 2021 / Published: 30 September 2021
(This article belongs to the Special Issue A Themed Issue in Memory of Academician Xing Qiyi (1911–2002))

Abstract

:
A phytochemical investigation on the roots of medicinal plant Eurycoma longifolia resulted in the isolation of 10 new highly oxygenated C20 quassinoids longifolactones G‒P (110), along with four known ones (1114). Their chemical structures and absolute configurations were unambiguously elucidated on the basis of comprehensive spectroscopic analysis and X-ray crystallographic data. Notably, compound 1 is a rare pentacyclic C20 quassinoid featuring a densely functionalized 2,5-dioxatricyclo[5.2.2.04,8]undecane core. Compound 4 represents the first example of quassinoids containing a 14,15-epoxy functionality, and 7 features an unusual α-oriented hydroxyl group at C-14. All isolated compounds were evaluated for their anti-proliferation activities on human leukemia cells. Among the isolates, compounds 5, 12, 13, and 14 potently inhibited the in vitro proliferation of K562 and HL-60 cells with IC50 values ranging from 2.90 to 8.20 μM.

1. Introduction

Quassinoids are a class of highly oxygenated degraded triterpenoids mainly distributed in plant family Simaroubaceae [1]. Based on the number of carbon atoms involving the construction of their basic scaffolds, quassinoids are commonly categorized into six distinct groups: C26, C25, C22, C20, C19, and C18 types [2]. Quassinoids have been reported to display a wide range of biological activities, including antitumor, antimalarial, anti-inflammatory, antiviral, neuroprotective, and antifeedant activities [2,3]. Especially since the discovery of bruceantin, a C20 quassinoid isolated from Brucea antidysenteria (Simaroubaceae) in the early 1970s that showed remarkable antileukemic activity, the antitumor activities of quassinoids have attracted extensive attention from both chemical and biological communities [4,5,6,7].
Eurycoma longifolia Jack (Simaroubaceae), commonly known as “Tongkat Ali”, is a flowering shrub plant that widely distributed in Southeast Asia [8]. The roots of E. longifolia were traditionally used by local people for the treatment of malaria, dysentery, glandular swelling, persistent fever, aches, and sexual insufficiency [8]. Besides, the antitumor activities of the crude extract of E. longifolia roots were reported in 2005 [9]. Previous phytochemical investigations on the roots of E. longifolia have afforded a wide variety of chemical components, including quassinoids, canthin-6-one alkaloids, β-carboline alkaloids, tirucallane-type triterpenes, squalene derivatives, and biphenyl neolignans [10]. Among them, quassinoids are the most characteristic chemical constituents of this plant [11,12,13].
Previously, our group had reported the isolation and characterization of six novelquassinoids (longifolactones A‒F) with unprecedented C26 or C20 scaffolds from the petroleum ether-soluble fraction of the ethanol extract of E. longifolia roots [14]. Among them, longifolactione F is the first example of quassinoids containing an unprecedented densely functionalized 2,5-dioxatricyclo [5.2.2.04,8]undecane ring system. In our continuing studies on searching structurally unique and biologically interesting metabolites from medicinal plants, the ethyl acetate-soluble fraction of the title plant was further investigated. As a result, longifolactones G‒P (110), 10 new C20 quassinoids, together with four known ones were isolated. Their structures and absolute configurations were unambiguously established by extensive spectroscopic data analysis and single-crystal X-ray diffraction experiment. Notably, compound 1 is the second member of the rare class of quassinoids featuring densely functionalized 2,5-dioxatricyclo[5.2.2.04,8]undecane core. Besides, compound 4 represents the first example of quassinoids containing a 14,15-epoxy functionality, and compound 7 features an unusual 14α-OH substituent that makes 7 the second member of this rare class of quassinoids so far. Herein, we reported the isolation and structure elucidation of these new quassinoids. In addition, the in vitro anti-proliferation activities of all isolates on two human leukemia cell lines (K562 and HL-60 cells) were also described.

2. Results and Discussions

2.1. Quassinoids Isolated from E. longifolia

The air-dried and powdered roots of E. longifolia (10 kg) were extracted with 95% ethanol under room temperature for five times. The ethanol extract (270 g) was suspended in water and partitioned successively with petroleum ether, ethyl acetate, and n-butanol. The ethyl acetate-soluble fraction was investigated in present study. By performing a series of charomatographic procedures on the aforementioned fraction, 10 new C20 quassinoids (longifolactones G‒P, 110), along with four known C20 quassinoids, chaparrolide (11) [15], 15β-hydroxyklaineanone (12) [16], 14,15β-dihydroxyklaineanone (13) [17], and eurycomanone (14) [18], were isolated (Figure 1).

2.2. Structure Elucidation of the New Quassinoids

Compound 1 was obtained as colorless needles. Its molecular formula was determined as C20H26O8 by the HR-ESI-MS ion peak at m/z 395.1696 [M + H]+ (calcd for C20H27O8, 395.1700) and 13C NMR data. The UV spectrum of 1 displayed absorption maxima at 241 nm. Its IR spectrum revealed the characteristic absorptions for hydroxyl (3455 cm−1) and carbonyl (1730 and 1667 cm−1) functional groups. In the 1H and 13C NMR spectra of 1, signals corresponding to two hydroxyl groups [δH 7.05 (1H, s) and 6.89 (1H, d, J = 5.7 Hz)], a ketone carbonyl (δC 199.7), a ester carbonyl (δC 171.5), a trisubstituted double bond [δH 6.07 (1H, br s); δC 163.3 and 125.6], a hemiketal carbon (δC 111.0), an oxygenated quaternary carbon (δC 82.9), four oxygenated methines [δH 5.45 (1H, m), 5.13 (1H, s), 4.72 (1H, dd, J = 4.6, 1.8 Hz), and 4.00 (1H, s); δC 85.5, 83.5, 82.7, and 69.5], three methines, a methylene, two quaternary carbons, and four methyl groups [δH 1.96 (3H, s), 1.70 (3H, s), 1.39 (3H, s), and 1.34 (3H, d, J = 7.2 Hz); δC 21.6, 13.0, 12.9, and 12.8] were observed, indicative of a C20 quassinoid skeleton for 1. With the aid of 2D NMR spectroscopic data, all proton and carbon resonances of 1 were assigned (Tables S1 and S2).
The above NMR spectroscopic data of 1 were closely similar to those of longifolactone F [14], suggesting the structural similarity of these two compounds. Different from longifolactone F, the NMR signals corresponding to a methylene group (CH2-3) and a methine group (CH-4) were replaced by resonances of a double bond [δH 6.07 (1H, br s); δC 163.3 and 125.6] in 1. In the HMBC spectrum, key correlations between H3-29 and C-3, H-5 and C-3, H2-6 and C-4 were observed, suggesting the presence of an α,β-unsaturated ketone motif in ring A of 1, which was also confirmed by the characteristic chemical shift values of C-2‒C-4 (δC 199.7, 125.6, and 163.3). After a comprehensive interpretation of its 1H–1H COSY and HMBC spectra, the gross structure of 1 was established as a C20 quassinoid with a rare 2,5-dioxatricyclo[5.2.2.04,8]undecane core (Figure 2).
In the NOESY spectrum of 1, key NOE correlations between H-1 and H-5/H-11, H-5 and H-9 were observed, indicating that these protons had the same orientation. Meanwhile, the NOE correlations between OH-14 and H-15/H3-30, H-13 and H3-30, H3-19 and H3-30 were observed, suggesting that these protons were located on the same face of the molecule (Figure 3). Finally, suitable crystals of 1 were acquired. The following X-ray diffraction analysis with Cu Kα radiation resulted in an excellent Flack parameter of 0.06 (4), which not only allowed the verification of the planar structure of 1 but also led to the establishment of its absolute configuration as 1S,5S,7R,8R,9R,10S,11R,12R,13S,14R,15R (Figure 4).
The molecular formula of 2 was deduced as C21H30O8 on the basis of its HR-ESI-MS data (m/z 433.1832 [M + Na]+; calcd for C21H30O8Na, 433.1833), and the 13C NMR data analysis. The 1H and 13C NMR spectroscopic data of 2 (Tables S1 and S2) highly resembled those of 6-dehydroxylongilactone [19], except for the presence of additional signals due to a hemiketal carbon (δC 102.5) and an oxygenated methyl group [δH 3.83 (3H, s); δC 52.7] in 2. Subsequently, detailed analysis of its 1H–1H COSY and HMBC spectra allowed the establishment of a 6/6/6/5 ring system for 2 that was identical to 6-dehydroxylongilactone. Besides, the HMBC correlation between 1′-OCH3 and C-16 indicated the presence of an extra methoxycarbonyl group in 2. Based on the molecular formula information, as well as the obvious down-field shift of C-15 (δC 102.5), the remaining methoxycarbonyl and hydroxyl groups were both assigned to attach to C-15, which was also confirmed by the HMBC correlation between H-14 and C-16 (Figure 2). Thus, the planar structure of 2 was established. Finally, the structure of 2 was fully resolved by an X-ray diffraction experiment. With an excellent Flack parameter of 0.09 (8), the absolute configuration of 2 was assigned as 1S,5S,7R,8R,9R,10S,11R,12R,13R,14S,15S (Figure 4).
The molecular formula of 3 was determined to be C20H28O5 on the basis of its sodiated molecular ion peak at m/z 371.1831 [M + Na]+ (calcd for C20H28O5Na, 371.1829) and 13C NMR data. The 1H and 13C NMR spectral data of 3 were similar to those of the co-isolated known compound chaparrolide (11), which indicated that 3 was also a C20 quassinoid. Compared with those of 11, the 1H and 13C NMR spectra of 3 showed additional signals for a cis-disubstituted double bond [δH 6.31 (1H, d, J = 9.6 Hz) and 5.76 (1H, d, J = 9.6 Hz); δC 132.7 and 130.2] and an exo-olefin group [δH 5.00 (1H, s) and 4.84 (1H, s); δC 145.8 and 111.3], while the signals corresponding to a ketone carbonyl, a methylene group, a methine group, and a methyl group were absent. In the 1H–1H COSY spectrum of 3, the correlation between H-11 and H-12 indicated that the C-11 in 3 was an oxygenated-substituted methine instead of the ketone carbonyl in 11 (Figure 2). Moreover, the observed HMBC cross-peaks between H2-29 and C-3/C-5, H-3 and C-5, H-3 and C-1 indicated the presence of two conjugated double bonds in ring A of 3 (Figure 2). Similarly, an X-ray diffraction experiment using Cu Kα radiation was performed, which led to the full assignment of planar structure and absolute configuration for 3 (1R,5S,7R,8S,9R,10S,11S,12R,13R,14S, Figure 4).
The molecular formula of 4 was assigned as C20H26O7 based on its HR-ESI-MS data (m/z 401.1574 [M + Na]+; calcd for C20H26O7Na, 401.1571) and 13C NMR spectroscopic data, 18 mass units less than the co-isolated known C20 quassinoid, 14,15β-dihydroxyklaineanone (13). The NMR spectra of 4 showed characteristic signals similar to those of 13, except for the presence of one oxygen-bearing methine [δH 3.36 (1H, s); δC 52.9] and one oxygenated bearing quaternary carbon (δC 67.9). Considering the molecular formula information, the two hydroxyl groups at C-14 and C-15 in 13 were replaced by an epoxide ring in 4. Furthermore, the NOE correlation between H-15 and H3-18 in the NOESY spectrum suggested that the epoxide ring had the β-orientation (Figure 3). Similar to 13, the structure with absolute configuration (1S,5S,7R,8S,9R,10S,11R,12R,13S,14R,15R) of 4 was definitively assigned by an X-ray diffraction experiment (Figure 4).
The molecular formula of 5 was determined as C20H26O7 by the HR-ESI-MS ion peak at m/z 401.1574 [M + Na]+ (calcd for C20H26O7Na, 401.1571) and 13C NMR data. The 1H and 13C NMR spectral data of 5 (Tables S1 and S2) were very similar to those of 11-dehydroklaineanone [20]. The main differences were that the signals corresponding to a methylene group [δH 3.69 (1H, dd, J = 19.4, 12.7 Hz) and 2.70 (1H, dd, J = 19.4, 6.6 Hz); δC 29.1] in the known compound were replaced by the signals due to an oxygenated methine [δH 5.42 (1H, d, J = 10.1 Hz); δC 67.3] in 5, suggesting the presence of an additional hydroxyl group at C-15 in 5. This assumption was further confirmed by the HMBC cross-peak between H-15 and C-16 (Figure 2). Subsequently, the planar structure and absolute configuration (1S,5S,7R,8S,9R,10S,12R,13R,14S,15R) of 5 were completely deduced by a single-crystal X-ray diffraction experiment (Figure 4).
The HR-ESI-MS of 6 displayed a sodiated molecular ion peak at m/z 435.1626 [M + Na]+, corresponding to a molecular formula of C20H28O9. Comparison of the 1H and 13C NMR spectral data of 6 (Tables S1 and S3) with those of Δ4,5,14-hydroxyglaucarubol [21] revealed that they were closely similar, except for signals for the endo-olefin (δC 130.1 and 127.5) and a methyl [δH 1.75 (3H, s); δC 20.2] in Δ4,5,14-hydroxyglaucarubol were replaced by signals of an exo-olefin [δH 4.98 (1H, s) and 4.74 (1H, s); δC 147.4 and 110.1] and a methine [δH 2.74 (1H, overlapped); δC 42.5] in 6. In the HMBC spectrum, correlations between H2-29 and C-3/C-5 indicated that the exo-olefin was located at C-4 (29) (Figure 2). Thus, the planar structure of 6 was established. Similarly, the relative stereostructure and absolute configuration (1S,2S,5S,7R,8R,9R,10S,11R,12R,13S,14R,15R) of 6 were established by a single-crystal X-ray diffraction experiment (Figure 4).
The molecular formula of 7 was deduced as C20H28O9 by its HR-ESI-MS data (m/z 435.1621 [M + Na]+; calcd for C20H28O9Na, 435.1626) and 13C NMR data. The NMR spectroscopic features of 7 were similar to those of 14-epi-13,21-dihydroeurycomanone [22], except for the presence of signals assigned to an oxygenated methine [δH 4.63 (1H, br s); δC 72.3] in 7, while the signal corresponding to a ketone carbonyl carbon was absent. The above data suggested that 7 was the C-2 hydroxylated derivative of 14-epi-13,21-dihydroeurycomanone. This assumption was confirmed by the spin system deduced from H-1 to H-3 in the 1H–1H COSY spectrum of 7 (Figure 2). Furthermore, the NOE correlation between H-2 and H3-19 in the NOESY spectrum suggested that the H-2 and H3-19 had the same orientation (Figure 3). Finally, with a Flack parameter of −0.12 (9), the absolute structure of 7 (1S,2S,5S,7R,8R,9R,10S,11R,12R,13S,14S,15R) was unambiguously established (Figure 4).
The HR-ESI-MS of compound 8 displayed a sodiated molecular ion peak at m/z 431.1311 [M + Na]+ (calcd for C20H24O9Na, 431.1313), allowing the determination of a molecular formula of C20H24O9 that was identical to the known C20 quassinoid 13-epi-eurycomadilactone [21]. The 1H and 13C NMR spectral data of 8 (Tables S1 and S3) closely resembled those of 13-epi-eurycomadilactone, combined with its molecular formula information, suggesting that 8 was a stereoisomer of the known compound. Further analysis of the 2D NMR data of 8 confirmed that 8 had the same planar structure as 13-epi-eurycomadilactone. Different from 13-epi-eurycomadilactone, the NOESY spectrum of 8 showed the correlation between H-13 and H2-30, indicating the α-orientation for the H3-18 in 8 (Figure 3). The structure with absolute configuration (1S,5S,7R,8R,9R,10S,11S,13R,14R,15R) of 8 was finally determined on the basis of an X-ray crystallography study by using the anomalous dispersion of Cu Kα radiation (Figure 4).
Compound 9 was assigned to possess a molecular formula of C20H26O9 by the HR-ESI-MS ion peak at m/z 433.1472 [M + Na]+ (calcd for C20H26O9Na, 433.1469) and 1D NMR spectral data analysis, which was two mass units more than that of 8. The 1H and 13C NMR spectra of 9 exhibited similar signals to those of 8 (Tables S1 and S3), except for the signal assigned to a ketone carbonyl (δC 197.0, C-2 in 8) was replaced by the signals of an oxygenated methine [δH 4.55 (1H, overlapped); δC 72.5] in 9. Thus, compound 9 was assumed to be a C-2 hydroxylated derivative of 8. This deduction was further verified by the spin system from H-1 to H-3 in the 1H–1H COSY spectrum of 9 (Figure 2). Furthermore, the α-orientation of the 2-OH was determined on the basis of key NOE correlation between H-2 and H3-19 (Figure 3). A further crystallographic analysis led to the unambiguous establishment of the structure and absolute configuration (1S,2S,5S,7R,8R,9R,10S,11S,13R,14R,15R) of 9 (Figure 4).
The molecular formula of 10 was deduced to be identical to that of 9 on the basis of its HR-ESI-MS data (m/z 433.1470 [M + Na]+; calcd for C20H26O9Na, 433.1469) and 13C NMR data. Comparison of the NMR data of 10 with those of 9 (Tables S1 and S3) indicated that 10 possessed the identical gross structure to 9. The main differences of the NMR spectral data between 10 and 9 were the obvious down-field shifts of C-5 (Δδ +5.1) and C-6 (Δδ +5.2) in 10, suggesting that 10 might be a C-5 epimer of 9. Further analysis of its 2D NMR spectroscopic data verified that 10 possessed the identical planar structure to 9. In the NOESY spectrum, NOE correlation between H-5 and H3-19 was observed, suggesting the β-orientation for H-5 in 10 (Figure 3). Similar to 19, the single-crystal X-ray diffraction study (Cu Kα) allowed the assignment of the complete stereochemistry of 10. As a result, the absolute configuration of 10 was definitively assigned to be 1S,2S,5R,7R,8R,9R,10S,11S,13R,14R,15R (Figure 4).

2.3. Anti-proliferation Activities of Isolated Quassinoids

The isolated compounds were tested for their anti-proliferation activities on two human leukemia cell lines, K562 and HL-60. As shown in Table S5, compounds 5, 12, 13, and 14 exhibited potent inhibitory effects on the proliferation of both K562 and HL-60 cells with IC50 values ranging from 2.90 to 8.20 μM.

3. Materials and Methods

3.1. General Methods

Melting points were measured on an X-5 melting point instrument (Fukai, Beijing, China) without correction. Optical rotations were determined in MeOH on a P-1020 polarimeter (JASCO, Tokyo, Japan) with a 1 cm cell at room temperature. UV spectra were acquired on a JASCO V-500 UV/vis spectrometer. IR spectra were obtained with a JASCO FT/IR-480 plus infrared spectrometer using KBr pellets. HR-ESI-MS data were collected using an Agilent 6210 TOF-MS spectrometer (Agilent Technologies, Santa Clara, CA, USA). Other experimental procedures were performed as described previously [14]. The human leukemia cell lines, HL-60 and K562, were purchased from the American Type Culture Collection (ATCC) and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine.

3.2. Plant Material

The roots of Eurycoma longifolia were collected from Malacca, Malaysia, in June 2014 and authenticated by Prof. Guang-Xiong Zhou (College of Pharmacy, Jinan University). A voucher specimen (No. 20140501) was deposited in the Center for Bioactive Natural Molecules and Innovative Drugs Research, College of Pharmacy, Jinan University.

3.3. Extraction and Isolation

The air-dried and powdered roots of E. longifolia (10 kg) were extracted with 95% (v/v) EtOH five times at room temperature. The combined EtOH extract was concentrated under vacuum to yield a crude extract (270 g), which was suspended in water and then partitioned successively with petroleum ether, ethyl acetate, and n-BuOH.
The ethyl acetate-soluble fraction (95 g) was subjected to silica gel column chromatography using gradient mixture of CHCl3-MeOH (100:0 → 0:100, v/v) as eluent to afford 10 major fractions (Fr.1–Fr.10).
Fr.2 (30.5 g) was further separated on a silica gel column (petroleum ether-EtOAc, 100:0 → 0:100, v/v) to give six subfractions Fr.2A–Fr.2F. Fr.2B (1.2 g) was purified by a Sephadex LH-20 column (CHCl3-MeOH, 1:1) followed by semipreparative HPLC (CH3CN-H2O, 35:65, v/v) to yield compounds 2 (5.0 mg) and 4 (8.0 mg). Then, Fr.2D (15.0 g) was separated over an ODS column (MeOH-H2O, 20:80 → 100:0) to afford six subfractions (Fr.2D-1–Fr.2D-6). Fr.2D-2 (3.0 g) was subsequently purified by semipreparative HPLC (MeOH-H2O, 30:70, v/v) to give compounds 1 (14.5 mg) and 11 (8.4 mg), and Fr.2D-4 (1.5 g) was also purified by preparative HPLC (MeOH-H2O, 35:65, v/v) to afford compound 3 (6.0 mg).
Fr.3 (5.0 g) was applied to a Sephadex LH-20 column (MeOH) and gave five subfractions Fr.3A–Fr.3E. Furthermore, Fr.3B was further subjected to preparative HPLC (MeOH-H2O, 32:68, v/v) to give compound 12 (45.0 mg).
Fr. 6 (20.0 g) was purified over an ODS column using MeOH-H2O (20:80 → 100:0, v/v) as eluent to afford eight subfractions (Fr.6A–Fr.6H). Fr.6B (8.0 g) was subjected to a Sephadex LH-20 column (MeOH) to yield five subfractions (Fr.6B-1–Fr.6B-5). Fr.6B-2 (3.0 g) was purified by semipreparative HPLC (CH3CN-H2O, 18:82, v/v) to give compounds 5 (7.4 mg), 6 (10.0 mg), 7 (40.5 mg), and 13 (1.5 g), respectively. Fr.6B-4 (500 mg) was purified by preparative HPLC (CH3CN-H2O, 18:82, v/v) to give compounds 8 (25.3 mg), 9 (5.2 mg), and 10 (5.1 mg).
Fr.9 (3.5 g) was applied to a Sephadex LH-20 column (MeOH) to obtain four subfractions Fr.9A–Fr.9D. Then, Fr.9C (1.2 g) was further subjected to preparative HPLC separation (CH3CN-H2O, 12:88, v/v) to afford compound 14 (80 mg).

3.4. Compounds Characterization

Longifolactone G (1): colorless needles (MeOH); mp 290–291 °C; [α ] D 25 +58.0 (c 0.55, MeOH); UV (CH3CN) λmax (log ε): 241 (3.81) nm; IR (KBr) vmax 3455, 2957, 1730, 1667, 1432, 1379, 1348, 1229, 1198, 1115, 1017, 973, 878 cm1; 1H and 13C NMR spectral data, see Tables S1 and S2; HR-ESI-MS m/z 395.1696 [M + H]+ (calcd for C20H27O8, 395.1700).
Longifolactone H (2): colorless needles (MeOH); mp 225–226 °C; [α ] D 25 −6.2 (c 0.34, MeOH); UV (CH3CN) λmax (log ε): 241 (4.01) nm; IR (KBr) vmax 3432, 2941, 1725, 1662, 1380, 1262, 1122, 998, 819, 564 cm1; 1H and 13C NMR spectral data, see Tables S1 and S2; HR-ESI-MS m/z 433.1832 [M + Na]+ (calcd for C21H30O8Na, 433.1833).
Longifolactone I (3): colorless needles (MeOH); mp 178–179 °C; [α ] D 25 +56.0 (c 0.46, MeOH); UV (CH3CN) λmax (log ε); 230 (3.97) nm; IR (KBr) vmax: 3468, 3346, 2953, 2904, 2577, 1727, 1496, 1411, 1316, 1226, 1128, 1057, 1015, 963, 813, 712, 638 cm1; 1H and 13C NMR spectral data, see Tables S1 and S2; HR-ESI-MS: m/z 371.1831 [M + Na]+ (calcd for C20H28O5Na, 371.1829).
Longifolactone J (4): colorless needles (MeOH); mp 255–256 °C; [α ] D 25 +18.2 (c 0.29, MeOH); UV (CH3CN) λmax (log ε): 241 (3.75) nm; IR (KBr) vmax 3450, 2943, 1726, 1656, 1434, 1379, 1347, 1261, 1196, 1123, 1063, 998, 959, 589, 523 cm−1; 1H and 13C NMR spectral data, see Tables S1 and S2; HR-ESI-MS m/z 401.1574 [M + Na]+ (calcd for C20H26O7Na, 401.1571).
Longifolactone K (5): colorless needles (MeOH-C5H5N); mp 266–267 °C; [α ] D 25 −7.2 (c 0.31, MeOH); UV (CH3CN) λmax (log ε): 240 (4.01) nm; IR (KBr) vmax 3429, 2944, 1726, 1660, 1435, 1381, 1261, 1122, 1064, 997, 964, 902, 819, 698, 449 cm−1; 1H and 13C NMR spectral data, see Tables S1 and S2; HR-ESI-MS m/z 401.1574 [M + Na]+ (calcd for C20H26O7Na, 401.1571).
Longifolactone L (6): colorless needles (MeOH); mp 265–266 °C, [α ] D 25 +22.2 (c 0.92, MeOH); UV (CH3CN) λmax (log ε): 195 (3.80) nm; IR (KBr) vmax: 3468, 3354, 2951, 2904, 2719, 1729, 1499, 1389, 1314, 1226, 1125, 1055, 964, 814 cm1; 1H and 13C NMR spectral data, see Tables S1 and S3; HR-ESI-MS m/z 435.1626 [M + Na]+ (calcd for C20H28O9Na, 435.1626).
Longifolactone M (7): colorless needles (MeOH); mp 300–301 °C; [α ] D 25 +10.1 (c 0.70, MeOH); UV (CH3CN) λmax (log ε): 198 (3.60) nm; IR (KBr) vmax 3304, 2886, 1737, 1654, 1507, 1456, 1426, 1332, 1281, 1234, 1081, 993, 917 cm−1; 1H and 13C NMR spectral data, see Tables S1 and S3; HR-ESI-MS m/z 435.1621 [M + Na]+ (calcd for C20H28O9Na, 435.1626).
Longifolactone N (8): colorless needles (MeOH); mp 248–249 °C, [α ] D 25 +44.6 (c 0.67, MeOH); UV (CH3CN) λmax (log ε): 240 (3.46) nm; IR (KBr) vmax: 3495, 3324, 1739, 1664, 1491, 1394, 1252, 1155, 1108, 1066, 973, 823 cm1; 1H and 13C NMR spectral data, see Tables S1 and S3; HR-ESI-MS m/z 431.1311 [M + Na]+ (calcd for C20H24O9Na, 431.1313).
Longifolactone O (9): colorless needles (MeOH); mp 245–246 °C, [α ] D 25 +4.2 (c 3.07, MeOH); UV (CH3CN) λmax (log ε): 198 (3.63) nm; IR (KBr) vmax: 3307, 2915, 1737, 1659, 1489, 1434, 1389, 1192, 1156, 1104, 974 cm1; 1H and 13C NMR spectral data, see Tables S1 and S3; HR-ESI-MS: m/z 433.1472 [M + Na]+ (calcd for C20H26O9Na, 433.1469).
Longifolactone P (10): colorless needles (MeOH); mp 265–266 °C; [α ] D 25 −1.3 (c 0.15, MeOH); UV (CH3CN) λmax (log ε): 196 (3.70) nm; IR (KBr) vmax: 3491, 3305, 1739, 1661, 1389, 1250, 1154, 1108, 1064, 975, 835 cm1; 1H and 13C NMR spectral data, see Tables S1 and S3; HR-ESI-MS m/z 433.1470 [M + Na]+ (calcd for C20H26O9Na, 433.1469).
Chaparrolide (11): colorless needles (MeOH); mp 184–185 °C; [α ] D 25 +15.6 (c 0.11, MeOH); UV (CH3CN) λmax (log ε): 196 (3.94) nm; IR (KBr) vmax 3484, 3369, 2961, 1720, 1381, 1242, 1098, 1054, 982, 810 cm1; 1H and 13C NMR spectral data, see Table S4 in Supplementary Materials; HR-ESI-MS m/z 389.1940 [M + Na]+ (calcd for C20H30O6Na, 389.1935).
15β-Hydroxyklaineanone (12): colorless needles (MeOH); mp 223–224 °C; [α ] D 25 +6.3 (c 1.73, MeOH); UV (CH3CN) λmax (log ε): 242 (4.05) nm; IR (KBr) vmax 3460, 2950, 1733, 1671, 1436, 1378, 1259, 1124, 1068, 1000, 958, 902, 814, 697, 633 cm−1; 1H and 13C NMR spectral data, see Table S4 in Supplementary Materials; HR-ESI-MS m/z 403.1734 [M + Na]+ (calcd for C20H28O7Na, 403.1727).
14,15β-Dihydroxyklaineanone (13): colorless needles (MeOH); mp 266–267 °C; [α ] D 25 +54.3 (c 0.51, MeOH); UV (CH3CN) λmax (log ε): 241 (4.05) nm; IR (KBr) vmax 3425, 2945, 1726, 1660, 1435, 1381, 1344, 1262, 1122, 1064, 998, 964, 902, 818, 698 cm−1; 1H and 13C NMR spectral data, see Table S4 in Supplementary Materials; HR-ESI-MS m/z 419.1674 [M + Na]+ (calcd for C20H28O8Na, 419.1676).
Eurycomanone (14): colorless needles (MeOH); mp 285–286 °C; [α ] D 25 +39.5 (c 0.65, MeOH); UV (CH3CN) λmax (log ε): 241 (3.46) nm; IR (KBr) vmax 3402, 2981, 2880, 1736, 1676, 1622, 1504, 1435, 1312, 1231, 1121, 1056, 985, 826, 765 cm−1; 1H and 13C NMR spectral data, see Table S4 in Supplementary Materials; HR-ESI-MS m/z 431.1314 [M + Na]+ (calcd for C20H24O9Na, 431.1313).

3.5. X-ray Crystallographic Analyses

The crystal data of compounds 110 were collected using an Oxford-Diffraction SuperNova diffractometer (Agilent Technologies, Yarnton, UK) with Cu Kα radiation. The crystal structures were solved by direct methods using the SHELXS program (Sheldrick, 2019) [23], and refined by the SHELXL-2018 program (Sheldrick, 2019) [23] and full-matrix least-squares calculation. Crystal data of compounds 110 in standard CIF format were deposited with the Cambridge Crystallographic Data Centre (CCDC 2,105,724 for 1, CCDC 2,105,722 for 2, CCDC 2,105,723 for 3, CCDC 2,105,731 for 4, and CCDC 2,105,730 for 5, CCDC 2,105,729 for 6, CCDC 2,105,727 for 7, and CCDC 2,105,725 for 8, CCDC 2,105,726 for 9, and CCDC 2,105,728 for 10).
Crystal data for compound 1 (M = 394.41 g/mol): orthorhombic, space group P212121, a = 7.17350(10) Å, b = 10.18810(10) Å, c = 24.5189(2) Å, β = 90°, V = 1791.95(3) Å3, Z = 4, T = 99.99(10) K, μ (Cu Kα) = 0.948 mm−1, Dcalc = 1.462 g/cm3, 21,948 reflections measured (7.21° ≤ 2θ ≤ 147.054°), 3593 unique (Rint = 0.0301, Rsigma = 0.0140) which were used in all calculations. The final R1 was 0.0306 (I > 2σ (I)), and wR2 was 0.0807 (all data). Flack parameter = 0.06(4).
Crystal data for compound 2 (M = 410.45 g/mol): monoclinic, space group P21, a = 8.0642(2) Å, b = 10.6239(3) Å, c = 11.9568(3) Å, β = 107.411(2)°, V = 977.44(5) Å3, Z = 2, T = 100.00(10) K, μ (Cu Kα) = 0.888 mm−1, Dcalc = 1.395 g/cm3, 9576 reflections measured (7.75° ≤ 2θ ≤ 146.844°), 3595 unique (Rint = 0.0302, Rsigma = 0.0220) which were used in all calculations. The final R1 was 0.0353 (I > 2σ (I)), and wR2 was 0.0946 (all data). Flack parameter = 0.09(8).
Crystal data for compound 3 (M = 364.44 g/mol): monoclinic, space group P21, a = 7.0067(2) Å, b = 13.4001(4) Å, c = 9.7581(3) Å, β = 90.421(2)°, V = 916.17(5) Å3, Z = 2, T = 293(2) K, μ (Cu Kα) = 0.795 mm−1, Dcalc = 1.328 g/cm3, 8696 reflections measured (9.062° ≤ 2θ ≤ 147.176°), 3440 unique (Rint = 0.0639, Rsigma = 0.0435) which were used in all calculations. The final R1 was 0.0355 (I > 2σ (I)), and wR2 was 0.0908 (all data). Flack parameter = 0.09(9).
Crystal data for compound 4 (M = 378.41 g/mol): orthorhombic, space group P212121, a = 9.63490(10) Å, b = 12.0407(2) Å, c = 15.6703(2) Å, β = 90°, V = 1817.93(4) Å3, Z = 4, T = 100.00(10) K, μ (Cu Kα) = 0.868 mm−1, Dcalc = 1.383 g/cm3, 14,343 reflections measured (9.262° ≤ 2θ ≤ 146.826°), 3607 unique (Rint = 0.0285, Rsigma = 0.0201) which were used in all calculations. The final R1 was 0.0284 (I > 2σ (I)), and wR2 was 0.0746 (all data). Flack parameter = −0.05(6).
Crystal data for compound 5 (M = 457.51 g/mol): monoclinic, space group I2, a = 7.84600(10) Å, b = 12.85380(10) Å, c = 22.0124(2) Å, β = 95.8390(10)°, V = 2208.45(4) Å3, Z = 4, T = 100.00(10) K, μ (Cu Kα) = 0.828 mm−1, Dcalc = 1.376 g/cm3, 20,973 reflections measured (7.976° ≤ 2θ ≤ 147.044°), 4407 unique (Rint = 0.0497, Rsigma = 0.0283) which were used in all calculations. The final R1 was 0.0334 (I > 2σ (I)), and wR2 was 0.0884 (all data). Flack parameter = 0.05(7).
Crystal data for compound 6 (M = 466.47 g/mol): orthorhombic, space group P212121, a = 13.8037(6) Å, b = 12.1850(6) Å, c = 12.0498(5) Å, β = 90°, V = 2026.75(16) Å3, Z = 4, T = 113(20) K, μ (Cu Kα) = 1.079 mm−1, Dcalc = 1.529 g/cm3, 7421 reflections measured (7.336° ≤ 2θ ≤ 147.508°), 3904 unique (Rint = 0.0401, Rsigma = 0.0517) which were used in all calculations. The final R1 was 0.0503 (I > 2σ (I)), and wR2 was 0.1464 (all data). Flack parameter = −0.04(9).
Crystal data for compound 7 (M = 430.44 g/mol): orthorhombic, space group P212121, a = 6.94750(10) Å, b = 9.86740(10) Å, c = 28.8229(4) Å, β = 90°, V = 1975.92(4) Å3, Z = 4, T = 100.00(10) K, μ (Cu Kα) = 0.983 mm−1, Dcalc = 1.447 g/cm3, 22,539 reflections measured (6.132° ≤ 2θ ≤ 147.044°), 3946 unique (Rint = 0.0695, Rsigma = 0.0368) which were used in all calculations. The final R1 was 0.0372 (I > 2σ (I)), and wR2 was 0.1016 (all data). Flack parameter = −0.12(9).
Crystal data for compound 8 (M = 480.45 g/mol): orthorhombic, space group P212121, a = 7.02070(10) Å, b = 13.3311(2) Å, c = 22.4885(3) Å, β = 90°, V = 2104.78(5) Å3, Z = 4, T = 100.01(10) K, μ (Cu Kα) = 1.097 mm−1, Dcalc = 1.516 g/cm3, 20,217 reflections measured (7.71° ≤ 2θ ≤ 147.848°), 4187 unique (Rint = 0.0429, Rsigma = 0.0296) which were used in all calculations. The final R1 was 0.0282 (I > 2σ (I)), and wR2 was 0.0734 (all data). Flack parameter = −0.01(6).
Crystal data for compound 9 (M = 410.41 g/mol): monoclinic, space group C2, a = 17.7027(6) Å, b = 8.4150(3) Å, c = 12.3274(3) Å, β = 99.070(3)°, V = 1813.43(10) Å3, Z = 4, T = 100.00(10) K, μ (Cu Kα) = 1.004 mm−1, Dcalc = 1.503 g/cm3, 16,975 reflections measured (7.262° ≤ 2θ ≤ 147.362°), 3635 unique (Rint = 0.0514, Rsigma = 0.0313) which were used in all calculations. The final R1 was 0.0388 (I > 2σ (I)), and wR2 was 0.1080 (all data). Flack parameter = 0.10(9).
Crystal data for compound 10 (M = 428.42 g/mol): orthorhombic, space group P212121, a = 7.2511(2) Å, b = 10.6856(3) Å, c = 24.0611(9) Å, β = 90°, V = 1864.31(10) Å3, Z = 4, T = 100.00(10) K, μ (Cu Kα) = 1.042 mm−1, Dcalc = 1.526 g/cm3, 17,396 reflections measured (7.348° ≤ 2θ ≤ 147.984°), 3693 unique (Rint = 0.0511, Rsigma = 0.0405) which were used in all calculations. The final R1 was 0.0375 (I > 2σ (I)), and wR2 was 0.0896 (all data). Flack parameter = 0.07(10).

3.6. Cell Proliferation Assay

HL-60 and K562 cells were cultured in 96-well plates and incubated at 37 °C, 5% CO2 incubator. After incubation for 24 h, the cell supernatants were discarded and supplemented with cell culture medium containing compounds at different concentrations. At 48 h after incubation, the cell supernatants in each well were removed and replaced with 100 μL culture medium containing 10 μL of cell counting kit-8 (Sigma-Aldrich, St. Louis, MO, USA), followed by incubation at 37 °C, 5% CO2 for 2 h. The absorbance at 450 nm of the cells was measured using a Plate Reader. Cell proliferation was calculated according to the OD450 value in cells that were treated with or without compounds.

4. Conclusions

In summary, a further phytochemical study on the roots of the medicinal plant Eurycoma longifolia resulted in the isolation and characterization of 14 highly oxygenated C20 quassinoids, including 10 new ones (longifolactones G‒P, 110). Structurally, compound 1 is the second member of a rare class of quassinoids featuring an unusual 2,5-dioxatricyclo[5.2.2.04,8]undecane ring system. Compound 4 possesses a 14,15-epoxy functionality that is unprecedented in quassinoids, and compound 7 features an unusual α-oriented hydroxyl group at C-14. In addition, compounds 5, 12, 13, and 14 showed potent anti-proliferation activities on two human leukemia cell lines, K562 and HL-60.

Supplementary Materials

The following are available online, Detailed UV, IR, HR-ESI-MS, and NMR spectra of compounds 114, as well as crystallographic data of compounds 110 are available as Supplementary Materials.

Author Contributions

W.-Q.Y. and W.T. performed the isolation, purification, structure determination, and written the manuscript. X.-J.H. performed the structural identification of the compounds. J.-G.S. conducted the single crystal X-ray diffraction experiments. Y.-Y.L. worked in biological experiments. Y.X. and C.-L.F. performed the extraction, isolation and structural identification of the compounds. Y.W., Z.-L.W., and W.-C.Y. designed the whole experiments and revised the paper. All authors have read and agreed to the published version of the manuscript.

Funding

This work was financially supported by the National Key R&D Program of China (2018YFC1706200 and 2017YFC1703800), the National Natural Science Foundation of China (81803379, 82003610, and 82104539), the Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program (2017BT01Y036), and the Key-Area Research and Development Program of Guangdong Province (2020B1111110004).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

All data supporting this study is available in the manuscript and the Supplementary Materials.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds 114 are available from the authors.

References

  1. Guo, Z.; Vangapandu, S.; Sindelar, R.W.; Walker, L.A.; Sindelar, R.D. Biologically active quassinoids and their chemistry: Potential leads for drug design. Curr. Med. Chem. 2005, 12, 173–190. [Google Scholar] [CrossRef] [PubMed]
  2. Duan, Z.K.; Zhang, Z.J.; Dong, S.H.; Wang, Y.X.; Song, S.J.; Huang, X.X. Quassinoids: Phytochemistry and antitumor prospect. Phytochemistry 2021, 187, 112769. [Google Scholar] [CrossRef] [PubMed]
  3. Zhao, W.Y.; Song, X.Y.; Zhao, L.; Zou, C.X.; Zhou, W.Y.; Lin, B.; Yao, G.D.; Huang, X.X.; Song, S.J. Quassinoids from Picrasma quassioides and their neuroprotective effects. J. Nat. Prod. 2019, 82, 714–723. [Google Scholar] [CrossRef]
  4. Polonsky, J. Quassinoid bitter principles. Fortschr. Chem. Org. Naturst. 1973, 30, 101–150. [Google Scholar] [PubMed]
  5. Polonsky, J. Quassinoid bitter principles II. Prog. Chem. Org. Nat. Prod. 1985, 47, 221–264. [Google Scholar] [CrossRef] [Green Version]
  6. Ravindar, K.; Caron, P.Y.; Deslongchamps, P. Anionic polycyclization entry to tricycles related to quassinoids and terpenoids: A stereocontrolled total synthesis of (+)-cassaine. J. Org. Chem. 2014, 79, 7979–7999. [Google Scholar] [CrossRef]
  7. Condakes, M.L.; Rosen, R.Z.; Harwood, S.J.; Maimone, T.J. A copper-catalyzed double coupling enables a 3-step synthesis of the quassinoid core architecture. Chem. Sci. 2019, 10, 768–772. [Google Scholar] [CrossRef] [Green Version]
  8. Bhat, R.; Karim, A.A. Tongkat Ali (Eurycoma longifolia Jack): A review on its ethnobotany and pharmacological importance. Fitoterapia 2010, 81, 669–679. [Google Scholar] [CrossRef] [PubMed]
  9. Nurhanan, M.Y.; Hawariah, L.P.A.; Ilham, A.M.I.; Shukri, M.A.M. Cytotoxic effects of the roots extracts of Eurycoma longifolia. Phytother. Res. 2005, 19, 994–996. [Google Scholar] [CrossRef]
  10. Rehman, S.U.; Choe, K.; Yoo, H.H. Review on a traditional herbal medicine, Eurycoma longifolia Jack (Tongkat Ali): Its traditional uses, chemistry, evidence-based pharmacology and toxicology. Molecules 2016, 21, 331. [Google Scholar] [CrossRef] [Green Version]
  11. Wong, P.F.; Cheong, W.F.; Shu, M.H.; The, C.H.; Chan, K.L.; AbuBakar, S. Eurycomanone suppresses expression of lung cancer tumor markers, prohibitin, annexin 1 and endoplasmic reticulum protein 28. Phytomedicine 2012, 19, 138–144. [Google Scholar] [CrossRef] [PubMed]
  12. Tung, N.H.; Uto, T.; Hai, N.T.; Li, G.; Shoyama, Y. Quassinoids from the roots of Eurycoma longifolia and their antiproliferative activity on human cancer cell lines. Pharmacogn. Mag. 2017, 13, 459–462. [Google Scholar]
  13. Hajjouli, S.; Chateauvieux, S.; Teiten, M.H.; Orlikova, B.; Schumacher, M.; Dicato, M.; Choo, C.Y.; Diederich, M. Eurycomanone and eurycomanol from Eurycoma longifolia Jack as regulators of signaling pathways involved in proliferation, cell death and inflammation. Molecules 2014, 19, 14649–14666. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Yang, W.Q.; Shao, X.H.; Deng, F.; Hu, L.J.; Xiong, Y.; Huang, X.J.; Fan, C.L.; Jiang, R.W.; Ye, W.C.; Wang, Y. Unprecedented quassinoids from Eurycoma longifolia: Biogenetic evidence and antifeedant effects. J. Nat. Prod. 2020, 83, 1674–1683. [Google Scholar] [CrossRef]
  15. Mitchell, R.E.; Stocklin, W.; Stefanovic, M.; Geissman, T.A. Chaparrolide and castelanolide, new bitter principles from Castela nicholsoni. Phytochemistry 1971, 10, 411–417. [Google Scholar] [CrossRef]
  16. Polonsky, J.; Baskevitch, Z.; Gottlieb, H.E.; Hagaman, E.W.; Wenkert, E. Carbon-13 nuclear magnetic resonance spectral analysis of quassinoid bitter principles. J. Org. Chem. 1975, 40, 2499–2504. [Google Scholar] [CrossRef]
  17. Chan, K.L.; Lee, S.P.; Sam, T.W.; Tan, S.C.; Noguchi, H.; Sankawa, U. 13β,18-dihydroeurycomanol, a quassinoid from Eurycoma longifolia. Phytochemistry 1991, 30, 3138–3141. [Google Scholar]
  18. Morita, H.; Kishi, E.; Takeya, K.; Itokawa, H.; Tanaka, O. New quassinoids from the roots of Eurycoma longifolia. Chem. Lett. 1990, 19, 749–752. [Google Scholar] [CrossRef]
  19. Morita, H.; Kishi, E.; Takeya, K.; Itokawa, H.; Iitaka, Y. Highly oxygenated quassinoids from Eurycoma longifolia. Phytochemistry 1993, 33, 691–696. [Google Scholar] [CrossRef]
  20. Itokawa, H.; Kishi, E.; Morita, H.; Takeya, K. Cytotoxic quassinoids and tirucallane-type triterpenes from the woods of Eurycoma longifolia. Chem. Pharm. Bull. 1992, 40, 1053–1055. [Google Scholar] [CrossRef] [Green Version]
  21. Meng, D.L.; Li, X.; Han, L.F.; Zhang, L.L.; An, W.W.; Li, X. Four new quassinoids from the roots of Eurycoma longifolia. Fitoterapia 2014, 82, 105–110. [Google Scholar] [CrossRef] [PubMed]
  22. Miyake, K.; Tezuka, Y.; Awale, S.; Li, F.; Kadota, S. Quassinoids from Eurycoma longifolia. J. Nat. Prod. 2009, 72, 2135–2140. [Google Scholar] [CrossRef] [PubMed]
  23. Lübben, J.; Wandtke, C.M.; Hübschle, C.B.; Ruf, M.; Sheldrich, G.M.; Dittrich, B. Aspherical scattering factors for SHELXL-model, implementation and application. Acta Crystallogr. A 2019, 75, 50–62. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Figure 1. Chemical structures of quassinoids isolated from the roots of E. longifolia.
Figure 1. Chemical structures of quassinoids isolated from the roots of E. longifolia.
Molecules 26 05939 g001
Figure 2. Key 1H–1H COSY and HMBC correlations of compounds 110.
Figure 2. Key 1H–1H COSY and HMBC correlations of compounds 110.
Molecules 26 05939 g002
Figure 3. Key NOESY correlations of compounds 110.
Figure 3. Key NOESY correlations of compounds 110.
Molecules 26 05939 g003
Figure 4. X-ray ORTEP drawings of compounds 110.
Figure 4. X-ray ORTEP drawings of compounds 110.
Molecules 26 05939 g004
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Yang, W.-Q.; Tang, W.; Huang, X.-J.; Song, J.-G.; Li, Y.-Y.; Xiong, Y.; Fan, C.-L.; Wu, Z.-L.; Wang, Y.; Ye, W.-C. Quassinoids from the Roots of Eurycoma longifolia and Their Anti-Proliferation Activities. Molecules 2021, 26, 5939. https://doi.org/10.3390/molecules26195939

AMA Style

Yang W-Q, Tang W, Huang X-J, Song J-G, Li Y-Y, Xiong Y, Fan C-L, Wu Z-L, Wang Y, Ye W-C. Quassinoids from the Roots of Eurycoma longifolia and Their Anti-Proliferation Activities. Molecules. 2021; 26(19):5939. https://doi.org/10.3390/molecules26195939

Chicago/Turabian Style

Yang, Wei-Qun, Wei Tang, Xiao-Jun Huang, Jian-Guo Song, Yue-Yue Li, Yu Xiong, Chun-Lin Fan, Zhen-Long Wu, Ying Wang, and Wen-Cai Ye. 2021. "Quassinoids from the Roots of Eurycoma longifolia and Their Anti-Proliferation Activities" Molecules 26, no. 19: 5939. https://doi.org/10.3390/molecules26195939

Article Metrics

Back to TopTop